Tech Company Financing Transactions
Engage Therapeutics Funding Round
TPG Biotech, Adage Capital Management and Lumira Capital joined a $23 million Series A funding round for Engage Therapeutics. This venture round was recorded on 9/28/2017.
Transaction Overview
Company Name
Announced On
9/28/2017
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Proceeds Purpose
Engage will use the proceeds from the financing to fund a Phase 2b clinical trial of its lead candidate Staccato® alprazolam, an acute epileptic treatment designed to stop seizure activity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Summit, NJ 07092
USA
Summit, NJ 07092
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Engage Therapeutics is focused on bringing patients with epilepsy suffering from uncontrolled seizures what could be the first rescue treatment with the potential to stop their seizures.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Mayes
Chief Medical Officer
Jouko Isojarvi
Chief Operating Officer
Mark Theeuwes
Browse more venture capital transactions:
Prev: 9/28/2017: interviewing.io venture capital transaction
Next: 9/28/2017: Fooda venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs